Skip to search formSkip to main contentSkip to account menu

ZEN-008

National Institutes of Health

Related topics

Related topics

2 relations
AN-152

Broader (1)

LHRH, lysine(6)-doxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).
5503Background: Zoptarelin (AEZS-108, AN-152, ZEN-008) is a luteinizing hormone-releasing hormone (LHRH)-cytotoxic hybrid… 
2006
2006
Phase I study of ZEN-008 (AN-152), a targeted cytotoxic LHRH analog, in female patients with cancers expressing LHRH receptors.
13146 Background: Human ovarian, endometrial, and breast cancers commonly express receptors for luteinizing hormone releasing… 
2006
2006
525 POSTER Targeting Doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152)
2006
2006
ZEN-008: eine Phase I Studie mit einem zytotoxischen GnRH-Analogon (AN-152) bei Patientinnen mit fortgeschrittenen, GnRH-Rezeptor I exprimierenden Karzinomen
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)